Zhenhua Hu

Dr. Zhenhua Hu

Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ZZZeyu Zhang
Zeyu Zhang
YDYang Du
Yang Du
XSXiaojing Shi
Xiaojing Shi
KWKun Wang
Kun Wang
QQQiaojun Qu
Qiaojun Qu
JTJie Tian
Jie Tian

3 February 2023 in Nature Reviews Bioengineering
Verified
Journal Article
Closed access
PDF file
KWKun Wang
Kun Wang
YDYang Du
Yang Du
ZZZeyu Zhang
Zeyu Zhang
KHKunshan He
Kunshan He
ZCZhongquan Cheng
Zhongquan Cheng
JTJie Tian
Jie Tian

12 August 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
BCBaisong Chang
Baisong Chang
DLDaifeng Li
Daifeng Li
YRYing Ren
Ying Ren
CQChunrong Qu
Chunrong Qu
XSXiaojing Shi
Xiaojing Shi
ZCZhen Cheng
Zhen Cheng

1 August 2021 in EBioMedicine
Verified
Journal Article
Open access
LZLianzhen Zhong
Lianzhen Zhong
DDDi Dong
Di Dong
XFXueliang Fang
Xueliang Fang
FZFan Zhang
Fan Zhang
NZNing Zhang
Ning Zhang
JTJie Tian
Jie Tian
Induction chemotherapy (ICT) plus concurrent chemoradiotherapy (CCRT) and CCRT alone were the optional treatment regimens in locoregionally advanced nasopharyngeal carcinoma (NPC) patients. Currently, the choice of them remains equivocal in clinical practice. We aimed to develop a deep learning-based model for treatment decision in NPC. A total of 1872 patients with stage T3N1M0 NPC were enrolled from four Chinese centres and received either ICT+CCRT or CCRT. A nomogram was constructed for predicting the prognosis of patients with different treatment regimens using multi-task deep learning radiomics and pre-treatment MR images, based on which an optimal treatment regimen was recommended. Model performance was assessed by the concordance index (C-index) and the Kaplan-Meier estimator. The nomogram showed excellent prognostic ability for disease-free survival in both the CCRT (C-index range: 0.888-0.921) and ICT+CCRT (C-index range: 0.784-0.830) groups. According to the prognostic difference between treatments using the nomogram, patients were divided into the ICT-preferred and CCRT-preferred groups. In the ICT-preferred group, patients receiving ICT+CCRT exhibited prolonged survival over those receiving CCRT in the internal and external test cohorts (hazard ratio [HR]: 0.17, p<0.001 and 0.24, p=0.02); while the trend was opposite in the CCRT-preferred group (HR: 6.24, p<0.001 and 12.08, p<0.001). Similar results for treatment decision using the nomogram were obtained in different subgroups stratified by clinical factors and MR acquisition parameters. Our nomogram could predict the prognosis of T3N1M0 NPC patients with different treatment regimens and accordingly recommend an optimal treatment regimen, which may serve as a potential tool for promoting personalized treatment of NPC. National Key R&D Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation, Strategic Priority Research Program of CAS, Project of High-Level Talents Team Introduction in Zhuhai City, Beijing Natural Science Foundation, Beijing Nova Program, Youth Innovation Promotion Association CAS.

27 April 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
BSBiluo Shen
Biluo Shen
ZZZhe Zhang
Zhe Zhang
XSXiaojing Shi
Xiaojing Shi
CCCaiguang Cao
Caiguang Cao
ZZZeyu Zhang
Zeyu Zhang
JTJie Tian
Jie Tian
Purpose: Surgery is the predominant treatment modality of human glioma but suffers difficulty on clearly identifying tumor boundaries in clinic. Conventional practice involves neurosurgeon’s visual evaluation and intraoperative histological examination of dissected tissues using frozen section, which is time-consuming and complex. The aim of this study was to develop fluorescent imaging coupled with artificial intelligence technique to quickly and accurately determine glioma in real-time during surgery. Methods: Glioma patients (N = 23) were enrolled and injected with indocyanine green for fluorescence image–guided surgery. Tissue samples (N = 1874) were harvested from surgery of these patients, and the second near-infrared window (NIR-II, 1000–1700 nm) fluorescence images were obtained. Deep convolutional neural networks (CNNs) combined with NIR-II fluorescence imaging (named as FL-CNN) were explored to automatically provide pathological diagnosis of glioma in situ in real-time during patient surgery. The pathological examination results were used as the gold standard. Results: The developed FL-CNN achieved the area under the curve (AUC) of 0.945. Comparing to neurosurgeons’ judgment, with the same level of specificity >80%, FL-CNN achieved a much higher sensitivity (93.8% versus 82.0%, P < 0.001) with zero time overhead. Further experiments demonstrated that FL-CNN corrected >70% of the errors made by neurosurgeons. FL-CNN was also able to rapidly predict grade and Ki-67 level (AUC 0.810 and 0.625) of tumor specimens intraoperatively. Conclusion: Our study demonstrates that deep CNNs are better at capturing important information from fluorescence images than surgeons’ evaluation during patient surgery. FL-CNN is highly promising to provide pathological diagnosis intraoperatively and assist neurosurgeons to obtain maximum resection safely. Trial registration: ChiCTR ChiCTR2000029402. Registered 29 January 2020, retrospectively registered

9 November 2020 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
CLCong Li
Cong Li
DDDi Dong
Di Dong
LLLiang Li
Liang Li
WGWei Gong
Wei Gong
XLXiaohu Li
Xiaohu Li
JTJie Tian
Jie Tian
Objective: The coronavirus disease 2019 (COVID-19) is rapidly spreading inside China and internationally. We aimed to construct a model integrating information from radiomics and deep learning (DL) features to discriminate critical cases from severe cases of COVID-19 using computed tomography (CT) images. Methods: We retrospectively enrolled 217 patients from three centers in China, including 82 patients with severe disease and 135 with critical disease. Patients were randomly divided into a training cohort (n = 174) and a test cohort (n = 43). We extracted 102 3-dimensional radiomic features from automatically segmented lung volume and selected the significant features. We also developed a 3-dimensional DL network based on center-cropped slices. Using multivariable logistic regression, we then created a merged model based on significant radiomic features and DL scores. We employed the area under the receiver operating characteristic curve (AUC) to evaluate the model's performance. We then conducted cross validation, stratified analysis, survival analysis, and decision curve analysis to evaluate the robustness of our method. Results: The merged model can distinguish critical patients with AUCs of 0.909 (95% confidence interval [CI]: 0.859-0.952) and 0.861 (95% CI: 0.753-0.968) in the training and test cohorts, respectively. Stratified analysis indicated that our model was not affected by sex, age, or chronic disease. Moreover, the results of the merged model showed a strong correlation with patient outcomes. Significance: A model combining radiomic and DL features of the lung could help distinguish critical cases from severe cases of COVID-19.